News stories about Aerie Pharmaceuticals (NASDAQ:AERI) have been trending positive this week, according to Accern Sentiment. The research firm identifies positive and negative news coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Aerie Pharmaceuticals earned a news sentiment score of 0.27 on Accern’s scale. Accern also assigned news stories about the company an impact score of 45.3769069395789 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Here are some of the news headlines that may have effected Accern’s rankings:
- Technical Perspectives on Drug Makers Stocks — Aerie Pharma … – PR Newswire (press release) (prnewswire.com)
- Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) – Hot Stock’s Watch List – Nasdaq Journal (press release) (nasdaqjournal.com)
- BRIEF-Aerie Pharmaceuticals Appoints Julia Williams As Director Of Medical Affairs (markets.businessinsider.com)
- Aerie Pharmaceuticals Names New Executive (socaltech.com)
- Aerie Pharmaceuticals Announces Appointment of Julia Williams as Director of Medical Affairs – Business Wire (press release) (businesswire.com)
AERI has been the subject of a number of research analyst reports. Guggenheim initiated coverage on Aerie Pharmaceuticals in a research note on Monday, October 23rd. They issued a “buy” rating and a $80.00 target price for the company. Zacks Investment Research cut Aerie Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, October 10th. Mizuho reissued a “buy” rating on shares of Aerie Pharmaceuticals in a research note on Friday, November 3rd. BidaskClub raised Aerie Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, December 5th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $62.00 target price on shares of Aerie Pharmaceuticals in a research note on Wednesday, October 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and thirteen have issued a buy rating to the company’s stock. Aerie Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $72.00.
Aerie Pharmaceuticals (NASDAQ:AERI) opened at $59.35 on Friday. The company has a current ratio of 15.24, a quick ratio of 15.24 and a debt-to-equity ratio of 0.78. The firm has a market capitalization of $2,180.00, a PE ratio of -17.72 and a beta of 1.11. Aerie Pharmaceuticals has a 52-week low of $37.80 and a 52-week high of $66.60.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).
Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.